跳轉至內容
Merck
全部照片(1)

文件

Y0001318

Cefpodoxime proxetil for impurity H identification

European Pharmacopoeia (EP) Reference Standard

同義詞:

Cefpodoxime proxetil

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C21H27N5O9S2
CAS號碼:
分子量::
557.60
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

cefpodoxime

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

−20°C

InChI

1S/C21H27N5O9S2/c1-9(2)33-21(30)35-10(3)34-19(29)15-11(6-31-4)7-36-18-14(17(28)26(15)18)24-16(27)13(25-32-5)12-8-37-20(22)23-12/h8-10,14,18H,6-7H2,1-5H3,(H2,22,23)(H,24,27)/b25-13-/t10?,14-,18-/m1/s1

InChI 密鑰

LTINZAODLRIQIX-FBXRGJNPSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Cefpodoxime proxetil for impurity H identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析證明 (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Hakki Yilmaz et al.
Current drug safety, 8(2), 145-147 (2013-07-13)
We report a case of acute interstitial nephritis (AIN) and immune hemolytic anemia (IHA) associated with cefpodoxime therapy. A patient with a recent history of cefpodoxime proxetil treatment presented with elevated serum creatinine, oliguria, nausea, vomiting, and dyspnea. Evidence of
Amrita Bajaj et al.
Drug development and industrial pharmacy, 39(5), 635-645 (2012-05-09)
Lipid based drug delivery systems have gained prominence in last decade for drugs with dissolution rate limited oral bioavailability. To improve the solubility, permeability and oral bioavailability of cefpodoxime proxetil, β-lactam antibiotic. It is BCS Class IV drug having solubility
Santosh V Gandhi et al.
Hindustan antibiotics bulletin, 51(1-4), 24-28 (2009-01-01)
Two accurate, precise, sensitive and economical procedures for simultaneous estimation of Cefpodoxime proxetil and Potassium clavulanate in tablet dosage form have been developed. The methods employed were absorbance correction method (I) and first order derivative spectroscopic method (II). The first
Md Salim Shakur et al.
Indian pediatrics, 44(11), 838-841 (2007-12-07)
In order to evaluate clinical and bacteriological efficacy of Cefpodoxime Proxetil (CP) in typhoid fever in comparison to cefixime (CF), we assessed 140 children with suspected typhoid fever. Fulfilling inclusion criteria finally 40 culture confirmed typhoid fever were allocated in
Abhijit A Date et al.
International journal of pharmaceutics, 329(1-2), 166-172 (2006-10-03)
Self-nanoemulsifying drug delivery systems (SNEDDS) were developed with the objective to overcome problems associated with the delivery of cefpodoxime proxetil (CFP), a poorly bioavailable high dose antibiotic having pH dependant solubility. Solubility of CFP in oily phases and surfactants was

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務